Physician profile
Michael L Johnson
NPI 1841304052
$866.20
in general payments reported to CMS, 2019-2025
12 companies · $23.62 in 2025
The $23.62 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.46 · 2020: $69.21 · 2021: $159 · 2023: $197 · 2024: $361 · 2025: $23.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $284.99 | 2019-2021 | |
| Alcon Vision LLC | $172.88 | 2023-2024 | Clareon, Rocklatan |
| Lumenis Be INC | $135.97 | 2024 | Optilight |
| Tarsus Pharmaceuticals, INC. | $52.24 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $44.76 | 2024-2025 | |
| Thea Pharma INC. | $32.60 | 2024 | Iyuzeh |
| Gilead Sciences, INC. | $31.16 | 2023 | |
| Abbvie INC. | $30.84 | 2024 | |
| Harrow Eye, LLC | $23.63 | 2024 | Vevye |
| Bausch & Lomb Americas INC. | $22.08 | 2024 | Miebo, Xiidra |
| Biotissue Holdings INC. | $19.05 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $16.00 | 2023 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.